Botulinum Toxin Type A Injection Near the Stylomastoid Foramen: A Safe and Effective Therapeutic Modality for Tinnitus in Patients With Hemifacial Spasm.

IF 1.9 3区医学 Q3 CLINICAL NEUROLOGY

Otology & Neurotology Pub Date : 2025-05-14 DOI:10.1097/MAO.0000000000004542

Lingxi Zhu, Lizhen Pan, Xiaolong Zhang, Yougui Pan, Lingjing Jin, Fei Teng

{"title":"Botulinum Toxin Type A Injection Near the Stylomastoid Foramen: A Safe and Effective Therapeutic Modality for Tinnitus in Patients With Hemifacial Spasm.","authors":"Lingxi Zhu, Lizhen Pan, Xiaolong Zhang, Yougui Pan, Lingjing Jin, Fei Teng","doi":"10.1097/MAO.0000000000004542","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to assess the efficacy and safety of botulinum toxin type A (BTX-A) injection near the stylomastoid foramen for tinnitus in patients with hemifacial spasm (HFS).Study design: Retrospective study from 2011 to 2024.Setting: Tongji Hospital affiliated to Tongji University in Shanghai, China.Patients: Patients with HFS combined with tinnitus.Intervention: BTX-A injection near the stylomastoid foramen.Main outcome measures: The efficacy of BTX-A was assessed based on subjective improvement reported by patients after 1 month. Adverse events were also documented.Results: A total of 869 HFS patients were analyzed, including 122 with tinnitus. Among the 122 patients with tinnitus, 110 received BTX-A injections near the stylomastoid foramen, and complete follow-up data were available for 105 of them. The 3.75 U group showed a higher improvement rate (69.2 ± 14.3%) compared with the 2.5 U group (46.3 ± 25.0%, p < 0.05). The majority received a 5 U dose, with a significantly higher improvement rate (76.9 ± 15.1%) compared with the 2.5 U group (p < 0.01). All reported adverse events were related to routine injection sites and were mild, requiring no special treatment. No adverse events related to BTX-A injection near the stylomastoid foramen were reported.Conclusion: In patients with HFS-associated tinnitus, additional injection of 5 U BTX-A near the stylomastoid foramen, targeting the stapedius muscle, proved to be an effective therapy with minimal adverse effects.","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otology & Neurotology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MAO.0000000000004542","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to assess the efficacy and safety of botulinum toxin type A (BTX-A) injection near the stylomastoid foramen for tinnitus in patients with hemifacial spasm (HFS).

Study design: Retrospective study from 2011 to 2024.

Setting: Tongji Hospital affiliated to Tongji University in Shanghai, China.

Patients: Patients with HFS combined with tinnitus.

Intervention: BTX-A injection near the stylomastoid foramen.

Main outcome measures: The efficacy of BTX-A was assessed based on subjective improvement reported by patients after 1 month. Adverse events were also documented.

Results: A total of 869 HFS patients were analyzed, including 122 with tinnitus. Among the 122 patients with tinnitus, 110 received BTX-A injections near the stylomastoid foramen, and complete follow-up data were available for 105 of them. The 3.75 U group showed a higher improvement rate (69.2 ± 14.3%) compared with the 2.5 U group (46.3 ± 25.0%, p < 0.05). The majority received a 5 U dose, with a significantly higher improvement rate (76.9 ± 15.1%) compared with the 2.5 U group (p < 0.01). All reported adverse events were related to routine injection sites and were mild, requiring no special treatment. No adverse events related to BTX-A injection near the stylomastoid foramen were reported.

Conclusion: In patients with HFS-associated tinnitus, additional injection of 5 U BTX-A near the stylomastoid foramen, targeting the stapedius muscle, proved to be an effective therapy with minimal adverse effects.

查看原文本刊更多论文

茎突孔附近注射A型肉毒毒素：一种安全有效的治疗面肌痉挛患者耳鸣的方法。

目的：评价茎突乳突孔附近注射A型肉毒毒素（BTX-A）治疗半面肌痉挛（HFS）患者耳鸣的疗效和安全性。研究设计：2011 - 2024年的回顾性研究。单位：中国上海同济大学附属同济医院。患者：HFS合并耳鸣患者。干预：在茎突孔附近注射BTX-A。主要观察指标：根据患者1个月后的主观改善情况评估BTX-A的疗效。不良事件也有记录。结果：共分析HFS患者869例，其中伴耳鸣122例。122例耳鸣患者中，110例在茎突乳突孔附近注射BTX-A，其中105例随访资料完整。3.75 U组改善率（69.2±14.3%）高于2.5 U组（46.3±25.0%,p < 0.05）。大多数患者接受5u剂量治疗，改善率（76.9±15.1%）显著高于2.5 U组（p < 0.01）。所有报告的不良事件都与常规注射部位有关，并且是轻微的，不需要特殊治疗。在茎突乳突孔附近注射BTX-A无不良事件报道。结论：hfs相关性耳鸣患者在茎突乳突孔附近靶向镫骨肌额外注射5u BTX-A是一种有效且副作用小的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Otology & Neurotology 医学-耳鼻喉科学

CiteScore

3.80

自引率

14.30%

发文量

509

审稿时长

3-6 weeks

期刊介绍： Otology & Neurotology publishes original articles relating to both clinical and basic science aspects of otology, neurotology, and cranial base surgery. As the foremost journal in its field, it has become the favored place for publishing the best of new science relating to the human ear and its diseases. The broadly international character of its contributing authors, editorial board, and readership provides the Journal its decidedly global perspective.